Sanofi (SNY) Stock Forecast & Price Target

$47.71 +0.21 (+0.44%)

(As of 12/20/2024 05:51 PM ET)

Sanofi - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 1 has given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for SNY.

Consensus Price Target

$57.50
20.52% Upside

According to the 3 analysts' twelve-month price targets for Sanofi, the average price target is $57.50. The highest price target for SNY is $60.00, while the lowest price target for SNY is $55.00. The average price target represents a forecasted upside of 20.52% from the current price of $47.71.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SNY Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$57.50	$57.50	$57.50	$60.00
Forecasted Upside	20.52% Upside	19.10% Upside	0.12% Upside	23.10% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Hold

First JFK… next Elon? (Ad)

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	20.52% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent SNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Argus 2 of 5 stars		Boost Target	Buy ➝ Buy	$55.00 ➝ $60.00	+13.92%
1/23/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight	$55.00	+8.20%
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
10/30/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/28/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell
3/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:50 AM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi recently reported earnings per share (EPS) of $1.57, significantly exceeding analysts' expectations of $0.22, indicating strong financial performance and effective management.
The company has shown a year-over-year revenue increase of 12.3%, demonstrating growth potential and resilience in its business operations.
With a current stock price of $48.51, Sanofi is trading within a reasonable range compared to its 12-month high of $58.97, suggesting potential for price appreciation.
Sanofi maintains a low debt-to-equity ratio of 0.17, indicating a conservative approach to leverage and financial stability, which can be attractive to risk-averse investors.
The firm has a solid return on equity (ROE) of 27.45%, reflecting efficient use of shareholders' equity to generate profits, which is a positive sign for potential investors.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Despite the positive EPS report, Sanofi's revenue of $13.44 billion fell short of analysts' expectations of $16.59 billion, raising concerns about future sales growth.
The stock has a relatively high price-to-earnings (P/E) ratio of 24.72, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
Sanofi's beta of 0.58 indicates lower volatility compared to the market, which may not appeal to investors seeking high-growth opportunities in more dynamic sectors.
Institutional ownership is at 10.04%, which may indicate a lack of confidence from larger investors, potentially affecting stock performance and liquidity.
The company operates in a highly competitive healthcare market, which poses risks related to market share and pricing pressures from competitors.

SNY Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $57.50, with a high forecast of $60.00 and a low forecast of $55.00.
: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There is currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SNY shares.
: According to analysts, Sanofi's stock has a predicted upside of 20.52% based on their 12-month stock forecasts.
: Analysts like Sanofi more than other "medical" companies. The consensus rating for Sanofi is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

First JFK… next Elon? (Ad)

I share with you in this special investigative documentary.

This page (NASDAQ:SNY) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target